These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Performance of a fluorescence polarization immunoassay for teicoplanin in serum.
    Author: Mastin SH, Buck RL, Mueggler PA.
    Journal: Diagn Microbiol Infect Dis; 1993 Jan; 16(1):17-24. PubMed ID: 8425374.
    Abstract:
    Teicoplanin is a new glycopeptide antibiotic that is structurally related to vancomycin, but has six major components and is > 90% protein bound. We have developed a competitive homogeneous fluorescence polarization immunoassay (FPIA) for the quantitative determination of teicoplanin in serum. The teicoplanin FPIA uses six serum-based calibrators over the range 0-100 micrograms/ml, with the lowest teicoplanin concentration at 5 micrograms/ml and a lower limit of detection of < 1.5 micrograms/ml. Samples with concentrations > 100 micrograms/ml can be analyzed after 1:5 dilution with serum. Intra- and interassay precision are < 2% and < 4.5%, respectively, for controls at 7.5, 35, and 75 micrograms/ml on an automated FPIA analyzer. Recovery results for 30 samples prepared from the teicoplanin analytical reference standard over the range 3.4-358 micrograms/ml were linearly correlated with target concentrations; the linear regression equation and correlation coefficient are FPIA = 0.976 x target + 0.120, r = 0.999. Abnormal levels of bilirubin, hemoglobin, albumin, triglycerides, or cholesterol did not significantly affect recovery. Cross-reactivity with vancomycin was < 0.2%, and there was no significant interference from above therapeutic levels of likely concomitant medications. Results on patient samples from the teicoplanin FPIA were highly correlated with both a high-performance liquid chromatography (HPLC) method (FPIA = 1.032 x HPLC + 2.79, r = 0.979, n = 203) and the reference teicoplanin microbiologic assay method (orthogonal regression; FPIA = 1.111 x bioassay + 2.107, r = 0.969, n = 1014). A version of the teicoplanin FPIA for use with a modular clinical research FPIA analyzer showed comparable performance in all respects to the automated assay.
    [Abstract] [Full Text] [Related] [New Search]